Revolutionizing CRBN-Based Degraders with Next-Generation Protein Degradation Tools to Drive Selectivity in Therapeutic Development
Time: 11:30 am
day: Conference Day One
Details:
- Discovering how innovative modifications in molecular glues and PROTACs are transforming neosubstrate selectivity while addressing safety challenges linked to offtarget effects
- Exploring advanced strategies like Lumit assays and CRISPR-engineered panels that enable rapid profiling of degradation potency, paving the way for cell-type-specific targeted therapies
- Learning about the cutting-edge HiBiT CRISPR tagging system and Lumit assays, which together offer powerful solutions for real-time monitoring and rapid endpoint assessment of protein degradation with unparalleled precision
